Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chirocaine Safety Comparison To Bupivacaine Must Await Resuscitation Data

Executive Summary

A safety comparison between Chiroscience/Zeneca's Chirocaine (levobupivacaine) and bupivacaine may depend on resuscitation data, FDA's Anesthetic & Life Support Drugs Advisory Committee members indicated Jan 12.
Advertisement

Related Content

Chiroscience Chirocaine Labeling Cites Possible Safety Advantage
Chiroscience Chirocaine Labeling Cites Possible Safety Advantage
Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study
Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study
Advertisement
UsernamePublicRestriction

Register

PS033468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel